ARTHUR-D.-LITTLE
15.3.2022 10:02:08 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced the promotion of nine of its consultants to the rank of Partner across a number of its global offices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005634/en/
Each new Partner has demonstrated their commitment to ADL, passion and dedication to the industries and clients they serve, and best-in-class experience and expertise. ADL credits a lot of its ongoing growth and success to the development, promotion and retention of its internal talent, with a recent survey on Vault acknowledging these values for setting ADL apart as an employer.
The latest promotions to Partner are as follows:
- Ryan Alnesayan, Partner, Public Services Practice, Riyadh. Leading ADL Riyadh’s office, Ryan has over 14 years of consulting and business advisory experience in strategic planning, economic development, and large-scale transformation projects, with a focus on Saudi Arabia.
- Marcus Beard, Partner, Risk Practice, Cambridge. Marcus’ area of expertise is risk management, in which he primarily focuses on developing next-generation risk management approaches, culture assessment, safety and risk governance and assurance, risk analysis, and executive leadership training, with deep industry experience in travel & transportation.
- Dr. Engin Beken, Partner, Operations Management Practice, Frankfurt & Vienna. Engin is a key expert in strategic performance improvement and digitalization. He is a strong contributor to ADL’s global operations management practice and works with our clients globally, especially in asset-heavy industries.
- Florence Carlot, Partner, Energy & Utilities Practice, Brussels. Florence focuses on strategy and organization in the energy & utilities industry. She has been working within the European energy and utilities sector for over 15 years, enabling large operational and strategic change initiatives across the energy value chain.
- Julien Duvaud-Schelnast, Partner, Telecommunications, Information Technology, Media & Electronics (TIME) Practice, Paris & Stockholm. Operating in both France and Sweden, Julien is an expert on trending topics within the TIME practice, including infrastructure, private networks and sustainability.
- Dr. Michael Eiden, Partner, Technology & Innovation Practice, London. Michael is the Global Head of Artificial Intelligence and Machine Learning at ADL. He is an industry expert with more than 20 years of hands-on experience in designing, developing and commercializing AI solutions in different industries.
- Ben Enejo, Partner, Healthcare & Life Sciences Practice, Boston. Ben is an experienced management consultant and industry expert, having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration; R&D transformation, including advanced technology application, increasing success for rare-disease drug development and launch; patient and drug safety; and quality and compliance excellence.
- Mitsuhiro Henry Umebayashi, Partner, Strategy & Organization Practice, Singapore. Henry leads the S&O practice in South-East Asia and supports clients from multiple industries, such as consumer goods, energy & utilities, infrastructure and healthcare. His main focus is supporting clients with business transformation and growth acceleration arising from management challenges such as sustainability, globalization and digitalization.
- Arjun Vir Singh, Partner, Financial Services Practice, Dubai. Arjun joined ADL in 2020 as the Head of Financial Services for the Middle East region. Actively engaged with fintech, payments, and digital banking, as well as the wider start-up ecosystem across the Middle East region and beyond, Arjun has deep sectorial knowledge. He has launched and managed a payments and fintech business for a large conglomerate across multiple markets in the Middle East and SEA region.
Ignacio Garcia Alves, Chairman and Chief Executive Officer of Arthur D. Little , comments: “I would like to congratulate our nine new Partners, who have worked hard and smart to become true entrepreneurs. Each promotion is richly deserved, and we are extremely grateful for the role they have played in the firm. At ADL we place tremendous value on our people. These nine colleagues have shown they are ready for the next step of their careers, and we are truly excited as they enter into their era of partnership.”
About Arthur D. Little
Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.
Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.
For further information, please visit www.adlittle.com or www.adl.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005634/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom